The independent medical news service

A variant of the interleukin 7 gene is associated with an increased risk of immune-related adverse events in people with cancer receiving immune checkpoint inhibitor therapy, suggests research.

A pooled analysis of clinical trial data points to a link between obesity and an increased risk for any-grade immune-related adverse events among people receiving nivolumab monotherapy for advanced cancer.

Stereotactic ablative body radiotherapy has high local efficacy and minimal impact on renal function in the long term among people with localized renal cell carcinoma, say researchers who conducted an individual patient data meta-analysis of the IROCK database.

Among patients with metastatic clear cell renal cell carcinoma, the outcomes of second-line treatment are similar irrespective of whether they received dual immunotherapy or IO plus a tyrosine kinase inhibitor in the first line, indicates a chart review.

The use of PI3K inhibitors for the treatment of cancer is associated with a high risk for developing cutaneous adverse events, suggests a meta-analysis published in JAMA Oncology.

People with intermediate- or poor-risk advanced renal cell carcinoma derive a significant progression-free survival benefit from the addition of cabozantinib to first-line nivolumab plus ipilimumab, indicates the COSMIC-313 trial.